Figure 5.
Risk of progression to advanced age-related macular degeneration (in at least one eye in patients with both eyes at risk) based on repeated-measures logistic regression analysis of Age-Related Eye Disease Study (AREDS) participants randomized to the AREDS combined treatment group (antioxidants plus zinc [AZ]) or placebo (P), by simplified risk score assigned at baseline.